Dyadic International, Inc. Stock Other OTC
Equities
US26745T1016
Biotechnology & Medical Research
Financials (USD)
Sales 2024 * | 4.2M | Sales 2025 * | 6.1M | Capitalization | 44.33M |
---|---|---|---|---|---|
Net income 2024 * | -22M | Net income 2025 * | -31M | EV / Sales 2024 * | 10.6 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 7.27 x |
P/E ratio 2024 * |
-2.32
x | P/E ratio 2025 * |
-1.7
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 48.58% |
Latest transcript on Dyadic International, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Mark Emalfarb
FOU | Founder | 69 | 78-12-31 |
Ping Rawson
DFI | Director of Finance/CFO | 48 | 16-05-31 |
Joseph Hazelton
COO | Chief Operating Officer | 48 | 21-11-08 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Emalfarb
FOU | Founder | 69 | 78-12-31 |
Jack Kaye
BRD | Director/Board Member | 80 | 15-04-30 |
Michael Tarnok
BRD | Director/Board Member | 69 | 14-06-11 |
1st Jan change | Capi. | |
---|---|---|
+3.16% | 42.11B | |
+48.83% | 40.08B | |
+8.38% | 40B | |
-10.82% | 26.87B | |
+8.21% | 24.58B | |
-22.90% | 18.44B | |
+1.35% | 11.94B | |
+32.76% | 11.66B | |
+6.97% | 11.01B |